List view / Grid view
Aurobac Therapeutics SAS - a €40m joint venture between Boehringer Ingelheim, Evotec and bioMérieux - has been launched to create the next generation of antimicrobials and diagnostics to fight antimicrobial resistance (AMR).
Psychedelic drugs are gaining popularity in the pharmaceutical R&D sector because of their apparent benefits for people suffering with neuropsychiatric disorders - and those which are resistant to existing therapies in particular. In this article, Imperial College London’s Professor David Nutt discusses the evidence underlying the development of psychedelic therapies…
The A2a receptor antagonist, which aims to inhibit the immunosuppression of T cells by adenosine, was in part designed using Exscientia’s 3D evolutionary artificial intelligence platform.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
